Cardiology (all articles)
Review | Management of short-term mechanical circulatory support for cardiogenic shock in adults in the intensive cardiac care unit
27 Jun, 2023 | 13:42h | UTC
Review | Hypertension management in patients with cardiovascular comorbidities
27 Jun, 2023 | 13:39h | UTCHypertension management in patients with cardiovascular comorbidities – European Heart Journal
Commentary on Twitter
Hypertension management in patients with cardiovascular comorbidities. A State-of-the-Art review just published in #EHJ.@escardio @ESC_Journals #CardioTwitter #hypertensionhttps://t.co/esgOEkxlta pic.twitter.com/xDRHSWn6sZ
— EHJ Editor-in-Chief (@ehj_ed) June 21, 2023
Review | Functional coronary angiography for the assessment of the epicardial vessels and the microcirculation
27 Jun, 2023 | 13:33h | UTC
Commentary on Twitter
? STATE OF THE ART: Functional coronary angiography for the assessment of the epicardial vessels and the microcirculation by Faria D, et al. https://t.co/gMUMILNCdc angiography-for-the-assessment-of-the-epicardial-vessels-and-the-microcirculation pic.twitter.com/mSUihEZf78
— EuroIntervention (@EuroInterventio) June 20, 2023
Secondary analysis of a RCT | Bempedoic acid reduces CV events in statin-intolerant patients with high CV risk
26 Jun, 2023 | 00:49h | UTCSummary: This secondary analysis of a Randomized Clinical Trial (RCT) evaluated the efficacy of bempedoic acid in primary prevention of cardiovascular events among statin-intolerant patients at high cardiovascular risk. From a total of 13,970 participants, 4206 met the criteria for primary prevention and were analyzed in this study. Those allocated to receive bempedoic acid showed a significant reduction in major cardiovascular events, reflected in a hazard ratio of 0.70.
The average age of this patient cohort was 68 years, and most participants (66%) were diagnosed with diabetes. Treatment with bempedoic acid also led to a significant 21.3% reduction in low-density lipoprotein cholesterol (LDL-C) levels and a 21.5% decrease in high-sensitivity C-reactive protein levels, suggesting improved cardiovascular health.
This study underscores the potential benefits of lipid-modulating therapy for primary prevention in high-risk patients, who are often undertreated. However, it is important to note the inherent limitations of this secondary analysis. The analysis was performed on a subgroup within a larger clinical trial, which could potentially lead to false-positive findings due to multiple testing. Furthermore, the results may not generalize to younger populations, those with lower pretreatment LDL-C levels, those without diabetes, or those with a lower baseline cardiovascular risk.
Article: Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients – JAMA (free for a limited period)
Editorial: Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Disease: Not a Statin Substitute but a Good Plan B – JAMA (free for a limited period)
See also: Visual Abstract
Commentary: Study Suggests Bempedoic Acid Could Find Role in Primary Prevention – HCP Live
Original Study: RCT | Bempedoic acid shows modest reduction in cardiovascular events for statin-intolerant patients
RCT | Shortened head-up tilt test is non-inferior to traditional method for suspected vasovagal syncope
26 Jun, 2023 | 00:42h | UTCSummary: The randomized clinical trial compared a short-duration head-up tilt test (HUTT) with the traditional longer-duration test for diagnosing suspected vasovagal syncope (VVS). The study involved 554 patients, half of which underwent the Fast protocol and the other half the Traditional protocol. The Fast protocol consisted of a 10-minute passive phase followed by a 10-minute nitroglycerin (NTG) phase if the passive phase yielded negative results, while the Traditional protocol included a 20-minute passive phase and a 15-minute NTG phase.
The findings showed no significant difference in the diagnostic value between the two protocols. Positive responses, identified by syncope induction amid hypotension or bradycardia, were seen in 60.3% of patients in the Fast protocol and 58.5% in the Traditional. However, there was a trend of less vasodepressor response in the Fast protocol during the passive phase.
This study suggests that the Fast HUTT protocol could replace the Traditional one, reducing test duration from 40 to 25 minutes without compromising diagnostic efficacy. However, the research didn’t assess the specificity of the Fast HUTT protocol in patients without a history of syncope, which serves as a limitation.
Article: Short-duration head-up tilt test potentiated with sublingual nitroglycerin in suspected vasovagal syncope: the fast Italian protocol – European Heart Journal (free for a limited period)
Commentary on Twitter
Short-duration head-up tilt test potentiated with sublingual nitroglycerin in suspected vasovagal syncope: the fast Italian protocol https://t.co/1s9phz40cU @escardio #EHJ #ESCYoung @rladeiraslopes @ehj_ed pic.twitter.com/Xrq3kn5xq2
— European Society of Cardiology Journals (@ESC_Journals) June 22, 2023
Review | How to treat diffuse large B-cell lymphoma: oncologic and cardiovascular considerations
26 Jun, 2023 | 00:33h | UTC
Commentary on Twitter
Are you struggling w/ how to protect patients w/ #DLBCL & CV comorbidities from #anthracycline #cardiotoxicity?
Follow this simple "how to guide" to cardioprotection by Dr. @SwethaKamMD et al in #JACCCardioOnc: https://t.co/d07eqOcB6V#lymphoma #CardioOnc #lymsm #CardioTwitter pic.twitter.com/W33FHjwA63
— JACC Journals (@JACCJournals) June 22, 2023
Cohort Study | Risk and outcome of infective endocarditis in streptococcal bloodstream infections according to streptococcal species
22 Jun, 2023 | 15:09h | UTC
Review | Early lead extraction for infected implanted cardiac electronic devices
22 Jun, 2023 | 15:03h | UTC
SCORE2-Diabetes | 10-year cardiovascular risk estimation in type 2 diabetes in Europe
22 Jun, 2023 | 14:57h | UTC
Commentary on Twitter
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe https://t.co/lkPTzqk0Kg @escardio #EHJ #ESCYoung pic.twitter.com/5TxesSwN1t
— European Society of Cardiology Journals (@ESC_Journals) June 14, 2023
Acute heart failure: differential diagnosis and treatment
21 Jun, 2023 | 13:37h | UTCAcute heart failure: differential diagnosis and treatment – European Heart Journal Supplements
Consensus Statement | Anatomy, imaging, and nomenclature of congenital aortic root malformations
21 Jun, 2023 | 13:25h | UTC
Position statement | Gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and/or anticoagulant therapy
21 Jun, 2023 | 13:22h | UTCPosition statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and/or anticoagulant therapy – Indian Journal of Gastroenterology (if the link is paywalled, try this one)
RCT | No superior recovery with minithoracotomy over sternotomy in mitral valve repair
20 Jun, 2023 | 12:51h | UTCMinithoracotomy vs Conventional Sternotomy for Mitral Valve Repair: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
Cohort Study | Five-year safety and efficacy of leadless pacemakers
20 Jun, 2023 | 12:40h | UTCFive-year safety and efficacy of leadless pacemakers in a Dutch cohort – Heart Rhythm
RCT | Testosterone replacement does not appear to increase cardiovascular events in hypogonadal men at high risk
19 Jun, 2023 | 14:13h | UTCCardiovascular Safety of Testosterone-Replacement Therapy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Presented today at #ENDO2023: In the TRAVERSE study, a randomized trial involving men with hypogonadism and preexisting or a risk of cardiovascular disease, testosterone therapy was noninferior to placebo with respect to major adverse cardiac events. https://t.co/V3FTTsOLd1
— NEJM (@NEJM) June 16, 2023
Review | Role of GLP1 receptor agonists in achieving weight loss and improving CV outcomes in people with overweight and obesity
19 Jun, 2023 | 13:40h | UTC
RCT | Mild hypercapnia after cardiac arrest shows no improvement in neurological outcomes vs. normocapnia
16 Jun, 2023 | 14:15h | UTCMild Hypercapnia or Normocapnia after Out-of-Hospital Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: New data supports current management of CO2 levels in cardiac arrest patients – UCD Dublin
Perspective | Benefits and pitfalls of social media in cardiology
16 Jun, 2023 | 14:13h | UTC
Commentary on Twitter
Medical #education has entered the #DigitalTransformation era ?
What is the role of #SoMe and multimedia platforms in #cardiology❓
Here is our view from the @JACCJournals #JACCCaseReports #SoMe Editors ❤️#CardioTwitter #MedEd #CardioEd
➡️Link to full paper below? pic.twitter.com/0W77HzoJ6Q
— Alessandro Beneduce (@ABeneduceMD) June 9, 2023
Brief Review | Why is cuff size so important and other factors that affect accurate blood pressure measurement
16 Jun, 2023 | 14:12h | UTC
Single-center cohort study | Low-risk PE patients with concerning CT findings – increased hospitalization, but no increased risk of mortality
16 Jun, 2023 | 13:49h | UTCCommentary: Acute Low-Risk Pulmonary Embolism and Concerning CT Findings – American College of Cardiology
M-A | Similar death rates in left main disease patients treated with PCI or CABG, both in patients with and without ACS
15 Jun, 2023 | 14:59h | UTCPercutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials – JAMA Cardiology (link to abstract – $ for full-text)
Commentary: CABG and PCI Comparable in ACS Patients With Left Main CAD – TCTMD
SR | Management of postpartum hypertensive disorders of pregnancy
14 Jun, 2023 | 14:37h | UTC
AHA Scientific Statement | Contaminant metals as cardiovascular risk factors
13 Jun, 2023 | 14:04h | UTCNews Release: Chronic exposure to lead, cadmium and arsenic increases risk of cardiovascular disease – American Heart Association
Top Things to Know: Contaminant Metals as CV Risk Factors – American Heart Association
Commentary: Toxic Metals: The Poisons that are “Killing Us Softly” – American Heart Association
Commentary on Twitter
⚠️ Chronic exposure to lead, cadmium & arsenic ⬆️ risk of CVD
Monitoring exposure in ?, ?& ?is important for reducing inequity in CVD risk, according to a new AHA scientific statement published in @JAHA_AHA
✍️ @GLamasMD @anavasachttps://t.co/v5TOvvettD pic.twitter.com/36iCmfDmDP
— AHA Science (@AHAScience) June 12, 2023
Consensus Statement | Three-dimensional transesophageal echocardiography
13 Jun, 2023 | 14:02h | UTC
Machine learning proves effective in predicting left ventricular hypertrophy through ECG analysis, study shows
13 Jun, 2023 | 13:57h | UTC
Commentary on Twitter
Predicting left ventricular hypertrophy from the 12-lead electrocardiogram in the UK Biobank imaging study using #MachineLearning https://t.co/3pnVQtkPH5 #EHJDigital #WhyCMR @BruiningNico @rafavidalperez @GerdHindricks @rbcasado pic.twitter.com/jbjuBJVIHW
— European Society of Cardiology Journals (@ESC_Journals) June 2, 2023